Bruce B Duncan
Bruce B Duncan
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history [0.03%]
具有心血管益处的降糖药作为人类生命史关键要素的调节剂
Angelo Avogaro,Saula Vigili de Kreutzenberg,Mario Luca Morieri et al.
Angelo Avogaro et al.
The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms making the best use of energy obtain the greatest fitness benefits. The trad...
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial [0.03%]
SURPASS-4试验中司美格鲁肽与甘精胰岛素对2型糖尿病患者肾脏结局影响的预设事后分析：一项开放标签、随机、三期试验
Hiddo J L Heerspink,Naveed Sattar,Imre Pavo et al.
Hiddo J L Heerspink et al.
Background: In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide reduced HbA1c concentrations, bodyweight, and blood pressure more than titrated daily insulin glargine in people with type 2 diabetes...
Adrenal surgery for bilateral primary aldosteronism: an international retrospective cohort study [0.03%]
双侧原发性醛固酮增多症的肾上腺手术：一项国际回顾性队列研究
Tracy Ann Williams,Siyuan Gong,Yuya Tsurutani et al.
Tracy Ann Williams et al.
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study [0.03%]
2021年全球1型糖尿病发病、患病和死亡率及2040年预测：建模研究
Gabriel A Gregory,Thomas I G Robinson,Sarah E Linklater et al.
Gabriel A Gregory et al.
Background: Accurate data on type 1 diabetes prevalence, incidence, associated mortality and life expectancy are crucial to inform public health policy, but these data are scarce. We therefore developed a model based on a...
Growing global burden of type 1 diabetes needs multitiered precision public health interventions [0.03%]
全球1型糖尿病负担加重 需要多层面的精准公共卫生干预措施
Serena Jingchuan Guo,Hui Shao
Serena Jingchuan Guo
Francine Ostrem
Francine Ostrem
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT [0.03%]
接受依洛尤单抗治疗80周的杂合子家族性高胆固醇血症儿科患者：HAUSER-RCT的单臂、多中心、开放标签扩展试验
Raul D Santos,Andrea Ruzza,G Kees Hovingh et al.
Raul D Santos et al.
Background: The HAUSER-RCT study showed that 24 weeks of evolocumab (a proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitor) in paediatric patients with heterozygous familial hypercholesterolaemia was safe and ...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2022 Oct;10(10):732-740. DOI:10.1016/S2213-8587(22)00221-2 2022
Robert A Hegele
Robert A Hegele